Results 51 to 60 of about 198 (126)

Design, synthesis and biological evaluation of <italic>S</italic>-DAPY derivatives as novel HIV-1 inhibitors [PDF]

, 2015
Erik De Clercq, Dirk Daelemans, Zheng-Yong Wan, Fen‐Er Chen   +3 more
openalex   +1 more source

Covalently Targeted Highly Conserved Tyr318 to Improve the Drug Resistance Profiles of HIV-1 NNRTIs: A Proof-of-Concept Study. [PDF]

Int J Mol Sci, 2023
Zhou Z, Meng B, An J, Zhao F, Sun Y, Zeng D, Wang W, Gao S, Xia Y, Dun C, De Clercq E, Pannecouque C, Zhan P, Kang D, Liu X.   +14 more
europepmc   +1 more source

Fragment Hopping-Based Design of Novel Biphenyl-DAPY Derivatives as Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Significantly Improved Anti-Resistance Efficacy

, 2023
Ya-Li Sang, Christophe Pannecouque, Erik De Clercq, Shuai Wang, Fen‐Er Chen   +4 more
openalex   +1 more source

Diarylpyrimidine-Dihydrobenzyloxopyrimidine Hybrids: New, Wide-Spectrum Anti-HIV-1 Agents Active at (Sub)-Nanomolar Level.

, 2011
Here, we describe a novel small series of nonnucleoside reverse transcriptase inhibitors (NNRTIs) that combine peculiar structural features of diarylpyrimidines (DAPYs) and dihydro-alkoxy-benzyl-oxopyrimidines (DABOs).
ARTICO M, CLOTET B, ESTE, JA, GONZALEZ ORTEGA E, MAGA G, MAI, Antonello, NAWROZKIJ MB, ROTILI, Dante, SAMUELE A, TARANTINO D   +9 more
core   +1 more source

Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored "hydrophobic channel"

, 2018
A new series of diarylpyrimidines (DAPYs) were designed, synthesized and evaluated as novel HIV-1 NNRTIs to further explore the chemical space surrounding the "hydrophobic channel" of the NNRTI binding pocket (NNIBP), guided by the comprehensive analysis
Daelemans, Dirk, De Clercq, Erik, Huo, Zhipeng, Kang, Dongwei, Liu, Tao, Liu, Xinyong, Pannecouque, Christophe, Wu, Gaochan, Zhan, Peng, Zhou, Zhongxia   +9 more
core   +1 more source

Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: New, wide-spectrum anti-HIV-1 agents active at (Sub)-nanomolar level

, 2021
Here, we describe a novel small series of non-nucleoside reverse transcriptase inhibitors (NNRTIs) that combine peculiar structural features of diarylpyrimidines (DAPYs) and dihydro-alkoxy-benzyl-oxopyrimidines (DABOs).
Rotili D.
core  

Diarylpyrimidine−Dihydrobenzyloxopyrimidine Hybrids: New, Wide-Spectrum Anti-HIV-1 Agents Active at (Sub)-Nanomolar Level

, 2016
Here, we describe a novel small series of non-nucleoside reverse transcriptase inhibitors (NNRTIs) that combine peculiar structural features of diarylpyrimidines (DAPYs) and dihydro-alkoxy-benzyl-oxopyrimidines (DABOs).
Alberta Samuele (2060419), Antonello Mai (205768), Bonaventura Clotet (91238), Dante Rotili (462382), Domenico Tarantino (561187), Emmanuel Gonzalez-Ortega (2204734), Giovanni Maga (10904), José A. Esté (1705729), Marino Artico (2093173), Maxim B. Nawrozkij (2204731)   +9 more
core   +2 more sources

Reflections on the Rega Institute for Medical Research, at the fiftieth anniversary of the Rega Stichting vzw (Rega Instituut vzw, Rega Foundation). [PDF]

Antivir Chem Chemother, 2022
Clercq E.
europepmc   +1 more source

Role of Ligand Reorganization and Conformational Restraints on the Binding Free Energies of DAPY Non-Nucleoside Inhibitors to HIV Reverse Transcriptase

, 2012
Emilio Gallicchio
openalex   +2 more sources

Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors

, 2019
Ya-Li Sang, Sheng Han, Christophe Pannecouque, Erik De Clercq, Chunlin Zhuang, Fen‐Er Chen   +5 more
openalex   +1 more source